Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2012
Reporting Period: Specific event date (June 5, 2012)
Oragenics, Inc. entered into a worldwide exclusive channel collaboration with Intrexon Corporation to develop and commercialize lantibiotics, a novel class of broad-spectrum antibiotics, as active pharmaceutical ingredients (API) for treating infectious diseases in humans and companion animals.
Key Financial Metrics and Agreements
This filing details material definitive agreements rather than periodic financial performance. Key financial terms include:
- Equity Issuance: Oragenics issued 4,392,245 shares of common stock to Intrexon as a "Technology Access Fee."
- Profit Sharing: Oragenics will pay Intrexon 25% of gross quarterly profits derived from the sale of products developed under the collaboration.
- Future Milestone Payments: Additional shares or cash payments are due upon achieving specific regulatory and clinical milestones (ranging from 1.0% to 3.0% of "Base Shares").
- Debt Restructuring: An amendment to a security agreement with the Koski Family Limited Partnership (KFLP) was executed to secure the collaboration.
Note: The filing text does not provide specific values for revenue, net profit, operating cash flow, total debt, or liquidity ratios.
Material Changes and Agreements
The following material changes occurred on June 5, 2012:
- Exclusive Channel Collaboration Agreement (ECC): Grants Oragenics an exclusive worldwide license to use Intrexon's modular genetic engineering platform. Oragenics is responsible for funding development, preclinical/clinical trials, and commercialization. Intrexon handles technology discovery and cell-engineering.
- Stock Issuance Agreement (SIA): Authorizes the initial issuance of shares and future issuances based on milestones. Includes a standstill provision preventing Intrexon from seeking control or initiating M&A activities for three years.
- Amendment to Security Agreement:
- Excluded in-licensed technologies from the University of Florida Research Foundation from loan collateral.
- Added Oragenics' Differentially Protected Orthogonal Lanthionine Technology (DPOLT) to the collateral.
- Granted KFLP the right to cure breaches of the ECC by Intrexon and assume the agreement.
Outlook, Risks, and Contingencies
Outlook and Milestones: Future equity dilution is contingent on achieving regulatory and clinical milestones, including:
- Filing of the first Investigational New Drug (IND) application (1.0% of Base Shares).
- Dosing of the first patient in Phase 2 (1.5% of Base Shares).
- Dosing of the first patient in Phase 3 (2.0% of Base Shares).
- Filing of the first New Drug Application (NDA) or Biologics License Application (BLA) (2.5% of Base Shares).
- Granting of the first regulatory approval (3.0% of Base Shares).
Risks and Contingencies:
- Termination: The agreement cannot be terminated for 18 months. Afterward, Oragenics may terminate with 90 days' notice. Intrexon may terminate if Oragenics breaches the agreement or fails to pursue a "Superior Therapy."
- Unregistered Securities: The shares issued to Intrexon were not registered under the Securities Act, relying on Section 4(2) exemption for accredited investors.
- Registration Rights: Intrexon has "piggyback" registration rights and the right to participate in future "Qualified Financings" (raising at least $1,000,000) by purchasing up to 30% of the shares sold.
Investor Verification Checklist
- Verify the exact number of "Base Shares" outstanding to calculate the potential dilution from future milestone payments.
- Review the full text of the Exclusive Channel Collaboration Agreement (Exhibit 10.1) for redacted confidential terms regarding profit sharing exceptions and expense allocations.
- Confirm the current status of the loan agreement with the Koski Family Limited Partnership and the specific terms of the DPOLT technology collateral.
- Assess the impact of the 25% gross profit sharing obligation on future margins once products reach commercialization.
- Monitor the 18-month non-termination window and the definition of "Superior Therapy" which could trigger early termination by Intrexon.